ReviewRomanian journal of ophthalmology
Adaptive Optics Imaging in Diabetic Retinopathy: A Comprehensive Review.
Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Time Series Segmentation in Adaptive Optics Ophthalmoscopy With Application to Flicker-Induced Vasodilation.Translational vision science & technology · 2026Article
- The positive correlation between the progressive photoreceptor damage and the increased macular leakage indicating the severity of diabetic retinopathy.Journal of diabetes investigation · 2026Article
- Advances in diagnosing and treating diabetic retinopathy.Nature reviews. Endocrinology · 2026Review
- Retinal Microvascular Alterations in Diabetic Patients Assessed with Novel Imaging Techniques.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diabetic retinopathy (DR), a major diabetes complication, is the fifth leading cause of global blindness and moderate-to-severe visual impairment. DR is categorized into non-proliferative and proliferative forms, with the latter involving neovascularization. Adaptive optics (AO) imaging provides high-resolution, in vivo visualization of retinal microstructures, offering enhanced insight into disease pathology. Methods: A comprehensive PubMed search was conducted for studies published before August 1, 2025, using the keywords "diabetic retinopathy" and "adaptive optics". The review focused on studies assessing cone photoreceptors, retinal vasculature, and clinical signs using AO imaging. Results: Forty-two studies were included. Many examined cone photoreceptor integrity across DR stages, with or without diabetic macular edema (DME). AO imaging revealed microstructural changes, enabling the correlation of cone metrics with other imaging modalities, including optical coherence tomography angiography, electroretinography, microperimetry, and color vision tests. Several studies analyzed capillary-level vascular alterations and their association with DR severity and DME. Some works have integrated AO data with blood flow assessments using techniques such as laser speckle flowgraphy and AO scanning laser ophthalmoscopy. Lastly, several studies have identified clinical signs related to DR and described their features on AO imaging. Discussion: Adaptive optics imaging reveals early and progressive alterations in photoreceptors, retinal microvasculature, and clinical signs such as microaneurysms and hard exudates in diabetic retinopathy, supporting its role as a valuable tool for understanding disease mechanisms and guiding early diagnosis and monitoring. Conclusions: Adaptive optics is a valuable imaging tool that improves understanding of retinal microarchitecture in diabetic retinopathy. It aids diagnosis, monitoring, and prognosis by enabling detailed evaluation of cellular and vascular alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.